About Us

We are a clinical stage immuno-oncology company that develops chimeric antigen receptors (CAR)-T cell therapeutics and a Guanylyl Cyclase C (GCC) cancer vaccine.

Our focus

The focus behind the incorporation of our company is to develop (from clinical trials and FDA approvals through to manufacturing and sales) solid tumor cancer CAR-Ts that treat metastatic GI cancers by using GCC CAR-T therapies.

To achieve this goal, we have obtained a license for all GCC CAR-T-related patents and know-hows from Targeted Diagnostics & Therapeutics, Inc. (TDT), and our merger with Viral Gene, Inc., a company that develops virus-based cancer immunotherapeutics, will help position us as a leader in GCC CAR-T therapeutics.


Company Overview


Advisory Board